Switching Cholesterol Drugs May Be Fatal: Study

Law360, New York (September 5, 2007, 12:00 AM EDT) -- A new study backed by Pfizer Inc. suggests that patients switching from Pfizer's cholesterol-lowering drug Lipitor to zimvastin, a generic version of Merck & Co.'s Zocor, are 30% more likely to die of heart attacks, strokes and other cardiovascular problems.

The study drew on medical records of patients between 1997 to 2005, all of whom took Lipitor for at least six months — 2,511 patients switched to zimvastin after at least six months, while 9009 remained on Lipitor.

Patients used in the study switched drugs for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.